D J Goldstein

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Fluoxetine in medically stable, depressed geriatric patients: effects on weight
    D J Goldstein
    Lilly Research Laboratories, Indianapolis, IN 46285 2128, USA
    J Clin Psychopharmacol 17:365-9. 1997
  2. ncbi Study of the analgesic effect of lanepitant in patients with osteoarthritis pain
    D J Goldstein
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Clin Pharmacol Ther 67:419-26. 2000
  3. ncbi Olanzapine-exposed pregnancies and lactation: early experience
    D J Goldstein
    Lilly Research Laboratories, Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis, USA
    J Clin Psychopharmacol 20:399-403. 2000
  4. ncbi Lanepitant, an NK-1 antagonist, in migraine prevention
    D J Goldstein
    Neuroscience Research, Lilly Research Laboratories, Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis, IN 46285 2033, USA
    Cephalalgia 21:102-6. 2001
  5. ncbi Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial
    D J Goldstein
    Neuroscience Division, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Lancet 358:1230-4. 2001
  6. ncbi Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy
    D J Goldstein
    Department of Neuroscience Research, Lilly Research Laboratory, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 24:16-22. 2001
  7. ncbi Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction
    D J Goldstein
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
    J Clin Psychiatry 54:309-16. 1993

Detail Information

Publications7

  1. ncbi Fluoxetine in medically stable, depressed geriatric patients: effects on weight
    D J Goldstein
    Lilly Research Laboratories, Indianapolis, IN 46285 2128, USA
    J Clin Psychopharmacol 17:365-9. 1997
    ..Medically relevant weight loss in older patients treated with fluoxetine was uncommon...
  2. ncbi Study of the analgesic effect of lanepitant in patients with osteoarthritis pain
    D J Goldstein
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Clin Pharmacol Ther 67:419-26. 2000
    ..Substance P is present in synovial fluid and in excess in cerebral spinal fluid. We investigated the effect of lanepitant on pain caused by osteoarthritis to evaluate the role of neurokinin-1 blockade...
  3. ncbi Olanzapine-exposed pregnancies and lactation: early experience
    D J Goldstein
    Lilly Research Laboratories, Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis, USA
    J Clin Psychopharmacol 20:399-403. 2000
    ..At this time, olanzapine should only be used during pregnancy and lactation when the potential benefit justifies the potential risk to the fetus or infant...
  4. ncbi Lanepitant, an NK-1 antagonist, in migraine prevention
    D J Goldstein
    Neuroscience Research, Lilly Research Laboratories, Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis, IN 46285 2033, USA
    Cephalalgia 21:102-6. 2001
    ..In this study lanepitant was not effective in preventing migraine, but was well tolerated. These results do not support a role for NK-1 antagonism in migraine prevention...
  5. ncbi Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial
    D J Goldstein
    Neuroscience Division, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Lancet 358:1230-4. 2001
    ..We have studied the efficacy of LY334370, a selective serotonin 1F (5-HT(1F)) receptor agonist with preclinical efficacy and no vasoconstriction, for migraine relief...
  6. ncbi Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy
    D J Goldstein
    Department of Neuroscience Research, Lilly Research Laboratory, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 24:16-22. 2001
    ..The adverse event diarrhea was more frequent for lanepitant-treated patients. Although well tolerated, lanepitant was ineffective in relieving pain of diabetic neuropathy...
  7. ncbi Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction
    D J Goldstein
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
    J Clin Psychiatry 54:309-16. 1993
    ....